{"id":3226,"company":{"country":"US","currency":"USD","exchange":"NEW YORK STOCK EXCHANGE, INC.","ipo":"2013-02-01","marketCap":69710.4,"name":"Zoetis Inc","phone":"19738227000.0","outstanding":460.32,"symbol":"ZTS","website":"https://www.zoetis.com/","industry":"Pharmaceuticals"},"price":165.005,"year":2024,"month":4,"day":3,"weekday":"Wednesday","title":"Impact of currency fluctuations on Zoetis Inc","date":"2024-04-03","url":"/posts/2024/04/03/ZTS","content":[{"section":"Positive impacts on Zoetis Inc","text":"Currency fluctuations can positively impact Zoetis Inc's multinational stock by creating additional revenue opportunities. When the value of the local currency depreciates against the currencies of countries where Zoetis operates, the company's exports become more competitive, leading to increased sales and profitability. For example, if the US dollar strengthens against other currencies, Zoetis, being a US-based company, can generate higher revenues from its international sales when converted back into US dollars."},{"section":"Negative impacts on Zoetis Inc","text":"Currency fluctuations also introduce currency risk, which can negatively impact Zoetis Inc's multinational stock. When the value of the local currency depreciates against the US dollar, it reduces the value of foreign earnings when converted back into US dollars. This can result in lower reported revenues and earnings, leading to a decline in the stock price. Additionally, currency fluctuations can increase the cost of imports, particularly if Zoetis relies heavily on imported raw materials or supplies."},{"section":"Real-world case study: Zoetis and Brexit","text":"One real-world case study illustrating the impact of currency fluctuations on Zoetis Inc's stock is the Brexit vote. When the British pound depreciated significantly against major currencies following the Brexit referendum in 2016, Zoetis experienced a negative impact. As a multinational company with operations in the UK, Zoetis faced increased costs for imported raw materials, affecting their profitability. The devaluation of the British pound also reduced the value of Zoetis' earnings in the UK when converted back into US dollars, leading to a decline in the stock price."},{"section":"Balanced assessment of currency risk","text":"Currency risk is an inherent part of operating as a multinational company. While currency fluctuations can create additional revenue opportunities, they also introduce uncertainty and potential financial risks. It is important for Zoetis Inc to implement risk management strategies such as hedging to mitigate the negative impact of currency fluctuations. By hedging against currency risk, Zoetis can protect itself from potential losses and ensure stability in its financial performance, thus creating more predictable returns for investors."}],"tags":["OverSold","Long","Pharmaceuticals"],"news":[{"category":"company","date":1712048820,"headline":"Expert Outlook: Zoetis Through The Eyes Of 4 Analysts","id":126809557,"image":"","symbol":"ZTS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3425629478"},{"category":"company","date":1712039340,"headline":"Zoetis price target lowered by $20 at Stifel, here's why","id":126809558,"image":"","symbol":"ZTS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3425446351"},{"category":"company","date":1712039220,"headline":"Zoetis price target raised by $20 at Stifel, here's why","id":126809559,"image":"","symbol":"ZTS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3425444505"},{"category":"company","date":1712003400,"headline":"Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors","id":126786211,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"PARSIPPANY, N.J., April 01, 2024--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors.","url":"https://finance.yahoo.com/news/zoetis-appoints-gavin-d-k-203000228.html"},{"category":"company","date":1711979271,"headline":"My Top 15 High Growth Dividend Stocks For April 2024","id":126777669,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325680818/image_1325680818.jpg?io=getty-c-w1536","symbol":"ZTS","publisher":"SeekingAlpha","summary":"Discover the recent performance of S\u0026P 500 ETF Trust, top dividend growth stocks for April 2024, and a watchlist's annualized return in this financial...","url":"https://seekingalpha.com/article/4681545-my-top-15-high-growth-dividend-stocks-for-april-2024"},{"category":"company","date":1711955400,"headline":"Is It Time to Buy the S\u0026P 500's 3 Worst-Performing Stocks of March?","id":126774950,"image":"https://g.foolcdn.com/editorial/images/771120/economic-crisis-stock-chart-falling-down-business-global-money-bankruptcy.jpg","symbol":"ZTS","publisher":"Yahoo","summary":"The S\u0026P 500 rose last month, but these stocks didn't.","url":"https://www.fool.com/investing/2024/04/01/time-to-buy-sp-500-worst-performing-stocks/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1711943700,"headline":"Zoetis Expands Board with New Director, Emphasizes Governance","id":126809562,"image":"","symbol":"ZTS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3424431986"},{"category":"company","date":1711900395,"headline":"12 Best S\u0026P 500 Stocks To Buy According to Analysts","id":126767975,"image":"https://s.yimg.com/ny/api/res/1.2/RDyivIe93nnoC.mIJbs..Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/5ae117b8c864f9c6d6031453261769fc","symbol":"ZTS","publisher":"Yahoo","summary":"In this piece, we will take a look at the 12 best S\u0026P 500 stocks to buy according to analysts. If you want to skip our coverage of the latest happenings surrounding one of America’s most widely followed stock indexes, then you can take a look at the 5 Best S\u0026P 500 Stocks To Buy […]","url":"https://finance.yahoo.com/news/12-best-p-500-stocks-155315533.html"},{"category":"company","date":1711828339,"headline":"11 Oversold Blue Chip Stocks to Buy Right Now","id":126764832,"image":"https://s.yimg.com/ny/api/res/1.2/q9lx8UcU5zp6f3hzMDPc_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/10a97c0166f5cfa1a63651b05b6f0d73","symbol":"ZTS","publisher":"Yahoo","summary":"In this article, we will take a look at the 11 oversold blue chip stocks to buy right now. To skip our analysis of the recent trends and market activity, you can go directly to see the 5 Oversold Blue Chip Stocks to Buy Right Now. The S\u0026P 500 Index, widely regarded as the leading […]","url":"https://finance.yahoo.com/news/11-oversold-blue-chip-stocks-195219274.html"},{"category":"company","date":1711797300,"headline":"Eli Lilly tops S\u0026P 500 healthcare sector in Q1 as weight loss frenzy continues","id":126761680,"image":"","symbol":"ZTS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3421891741"},{"category":"company","date":1711629240,"headline":"Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years","id":126755306,"image":"","symbol":"ZTS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3419274775"},{"category":"company","date":1711629000,"headline":"Zoetis to Host Webcast and Conference Call on First Quarter 2024 Financial Results","id":126730685,"image":"https://media.zenfs.com/en/business-wire.com/3e2420f6fc8a67f7767981fcaf20a098","symbol":"ZTS","publisher":"Yahoo","summary":"PARSIPPANY, N.J., March 28, 2024--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2024 financial results and respond to questions from financial analysts during the call.","url":"https://finance.yahoo.com/news/zoetis-host-webcast-conference-call-123000964.html"},{"category":"company","date":1711571215,"headline":"Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine","id":126718942,"image":"https://media.zenfs.com/en/Benzinga/200b6dfafc0651eaad7214917854d7f4","symbol":"ZTS","publisher":"Yahoo","summary":"The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a competing pain medication for dogs. Zoetis’ Librela is the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs. The medicine is administered monthly and offers a novel pain relief option, particularly relevant for older dogs. The European Commission said that Zoetis, while working on","url":"https://finance.yahoo.com/news/largest-animal-health-firm-zoetis-202655928.html"},{"category":"company","date":1711519380,"headline":"5 Best Healthcare Stocks to Buy in March 2024, According to Analysts","id":126709240,"image":"","symbol":"ZTS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3417089473"},{"category":"company","date":1711512720,"headline":"Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC), Merck \u0026 Company (MRK) and Zoetis (ZTS)","id":126709784,"image":"","symbol":"ZTS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3416988604"},{"category":"company","date":1711463234,"headline":"UPDATE 2-Zoetis in EU antitrust crosshairs over rival dog pain medicine","id":126691732,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker.  Antitrust regulators on both sides of the Atlantic have recently cracked down on Big Tech and Big Pharma acquiring start-ups or small rivals in order to shut them down in what is known as killer acquisitions.  Zoetis' Librela is currently the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.","url":"https://finance.yahoo.com/news/1-zoetis-eu-antitrust-crosshairs-142714371.html"},{"category":"company","date":1711460097,"headline":"Zoetis in EU antitrust crosshairs over rival dog pain medicine","id":126691734,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ZTS","publisher":"Yahoo","summary":"(Reuters) -EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker.  Antitrust regulators on both sides of the Atlantic have recently cracked down on Big Tech and Big Pharma acquiring start-ups or small rivals in order to shut them down in what is known as killer acquisitions.  Zoetis' Librela is currently the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.","url":"https://finance.yahoo.com/news/eu-targets-zoetis-antitrust-investigation-133457163.html"},{"category":"company","date":1711459800,"headline":"EU targets Zoetis in antitrust investigation over dog medicines","id":126691736,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"The European Commission on Tuesday said it had opened an antitrust investigation into possible breaches of EU competition rules by U.S. pet products maker Zoetis.  The EU's executive said Zoetis was seen to have prevented the market launch of a novel biologic medicine used to treat chronic pain in dogs, which would have been a competitor for its 'Librela' medicine.  The EU said this meant Zoetis might have engaged in \"exclusionary behaviour\" by terminating the development of an alternative product that was going to be commercialised in Europe by a third party.","url":"https://finance.yahoo.com/news/eu-targets-zoetis-antitrust-investigation-133000145.html"},{"category":"company","date":1711454413,"headline":"Investing in Zoetis (NYSE:ZTS) five years ago would have delivered you a 71% gain","id":126691738,"image":"https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","symbol":"ZTS","publisher":"Yahoo","summary":"Zoetis Inc. ( NYSE:ZTS ) shareholders might be concerned after seeing the share price drop 15% in the last month. On...","url":"https://finance.yahoo.com/news/investing-zoetis-nyse-zts-five-120013365.html"},{"category":"company","date":1711451160,"headline":"Zoetis comes under EU antitrust probe over dog pain drug","id":126690929,"image":"","symbol":"ZTS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3415717448"},{"category":"company","date":1711450731,"headline":"Zoetis to Be Investigated by EU Over Possible Breach of Competition Rules -- 2nd Update","id":126689090,"image":"","symbol":"ZTS","publisher":"Finnhub","summary":"By Ian Walker The European Commission has started a formal investigation into animal health company Zoetis to see if it broke competition rules by preventing the launch of a competing pain...","url":"https://finnhub.io/api/news?id=a439c83b30927e21a3efc1ff181fbc7c252cb581ec5233751f53da9bdce5efee"},{"category":"company","date":1711449088,"headline":"EU to Investigate Zoetis Over Possible Breach of Competition Rules -- Update","id":126688740,"image":"","symbol":"ZTS","publisher":"Finnhub","summary":"By Ian Walker The European Commission has started a formal investigation into animal health company Zoetis to see if it broke competition rules by preventing the launch of a competing pain...","url":"https://finnhub.io/api/news?id=edf01b27e6e86bc6c7bcc118869e4bcd9d2edd4e8f6b764662c5790bb464cec9"},{"category":"company","date":1711446963,"headline":"EU to Investigate Zoetis Over Possible Breach of Competition Rules","id":126688278,"image":"","symbol":"ZTS","publisher":"Finnhub","summary":"By Ian Walker The European Commission has started a formal investigation into animal health company Zoetis to see if it broke competition rules by preventing the launch of a competing pain...","url":"https://finnhub.io/api/news?id=6a833ce595df52054de253e3a5eb67703cfcd6debfc0b55cc8d46dd7fd944ee4"},{"category":"company","date":1711389580,"headline":"You Don't Have To Take Excess Risk To Beat The Market","id":126678251,"image":"","symbol":"ZTS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4680345-you-dont-have-to-take-excess-risk-to-beat-the-market"},{"category":"company","date":1711108810,"headline":"Does Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?","id":126642559,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...","url":"https://finance.yahoo.com/news/does-zoetis-nyse-zts-deserve-120010236.html"},{"category":"company","date":1711033914,"headline":"Zoetis: My Favorite Healthcare Stock Right Now","id":126620991,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1471774638/image_1471774638.jpg?io=getty-c-w1536","symbol":"ZTS","publisher":"SeekingAlpha","summary":"Zoetis has a strong position in the animal health market, with increased pricing power and limited competition. Click here for why I am bullish on ZTS stock.","url":"https://seekingalpha.com/article/4679714-zoetis-my-favorite-healthcare-stock-right-now"},{"category":"company","date":1711007580,"headline":"Discounted Zoetis price offers buing opportunity, says Argus","id":126644070,"image":"","symbol":"ZTS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3408438167"}]}